The earnings call highlighted strong clinical revenue growth and promising NGS performance, but these were overshadowed by significant declines in pharma services revenue, delays in product launches, and ongoing legal and market challenges. The sentiment is cautious as the company focuses on addressing these issues and realigning its strategy.

Company Guidance -

Q3 2025

During the NeoGenomics Second Quarter 2025 Financial Results Call, leadership provided several key metrics and guidance updates. The company reported Q2 revenue of $181 million, reflecting a 10% year-over-year growth, though slightly below their guidance range. Clinical revenue increased by 16% while nonclinical revenue declined by 26% due to weak pharma revenue. The NGS testing grew by 23%, although this was below the 25% target. Adjusted EBITDA was $10.7 million, and the company maintained cash and marketable securities of $164 million. Despite challenges, including a delayed PanTracer liquid biopsy launch, NeoGenomics revised its 2025 guidance to $720-$726 million in revenue and $41-$44 million in adjusted EBITDA, reflecting the current pharma market conditions and strategic adjustments. The company emphasized its commitment to achieving double-digit annual growth and enhancing operational efficiencies through initiatives like the LIMS project and digital pathology.

Clinical Revenue Growth

Total clinical revenue increased by 16% from the prior year, with organic clinical revenue growing by 13%, driven by a 10% increase in test volumes and a 3% increase in average unit price.

NGS Growth

NGS testing accounted for 32% of total clinical revenue and grew by 23% over the prior year, significantly ahead of the low to mid-teens NGS market growth rate.

Operational Efficiency

Investments in operating efficiencies, including the LIMS project and digital pathology, are positioning the company for more operating leverage in the latter half of the year.

Pathline Integration

The Pathline integration is on track and progressing well, contributing to the company's strategic expansion in the Northeast.

NeoGenomics (NEO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NEO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	0.02 / -	0.05	―	―	―
Jul 29, 2025	2025 (Q2)	0.02 / 0.03	0.03	0.00% (0.00)
Apr 29, 2025	2025 (Q1)	-0.01 / 0.00	-0.02	―
Feb 18, 2025	2024 (Q4)	0.03 / 0.04	0.03	33.33% (+0.01)
Nov 05, 2024	2024 (Q3)	0.01 / 0.05	0	―
Jul 29, 2024	2024 (Q2)	>-0.01 / 0.03	-0.05	160.00% (+0.08)
Apr 30, 2024	2024 (Q1)	-0.04 / -0.02	-0.09	77.78% (+0.07)
Feb 20, 2024	2023 (Q4)	-0.03 / 0.03	-0.06	150.00% (+0.09)
Nov 06, 2023	2023 (Q3)	-0.07 / 0.00	-0.14	―
Aug 08, 2023	2023 (Q2)	-0.11 / -0.05	-0.16	68.75% (+0.11)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NEO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$6.46	$5.25	-18.73%
Apr 29, 2025	$9.97	$6.58	-34.00%
Feb 18, 2025	$14.42	$12.40	-14.01%
Nov 05, 2024	$14.14	$14.93	+5.59%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.